Leadership
Investors & News
Contact

Pipeline

Pipeline Overview Ciprocopan (NXP100)NXP200 NXP900 Clinical Trials Publications

Investors & News

Investor Relations Overview Press Releases Stock Information SEC Filings Events & Presentations Governance Documents Email Alerts Contact Email Alerts

Contact Us
Disclaimer
Email Alerts
Governance Documents
Home
Investor Relations
Leadership
Ciprocopan (NXP100): Complement Factor B Inhibitor
NXP200: Paradox Breaker BRAF Inhibitor
NXP900: SRC/YES1 Kinase Inhibitor
Pipeline
Events & Presentations
Press Releases
Privacy Policy
Publications
SEC Filings
Stock Quote
Terms of Use
Clinical Trials

Press Releases

Overview
Press Releases
Stock Information
SEC Filings
Events & Presentations
Governance Documents
Email Alerts

NASDAQ: NVCT

Nuvectis Pharma

Pipeline
Clinical Trials
Publications
Leadership
News

Investors

Investor Relations Overview
Press Releases
Stock Information
SEC Filings
Events & Presentations
Governance Documents
Email Alerts

Contact

1 Bridge Plaza, 2nd Floor

Fort Lee, NJ 07024

© 2026 Nuvectis Pharma, Inc. All rights reserved.

Investor Relations Website By VendorGroup®